Breaking News

Perrigo Acquires Remaining Stake In Cobrek

December 28, 2012

Expands position in topical foam-based generics

Perrigo has signed and completed a definitive merger agreement, acquiring the remaining stake in Cobrek Pharmaceuticals, Inc., a privately-held drug development company, for approximately $45 million on a cash free and debt free basis.
In May 2008, Perrigo acquired an 18.5% minority stake in Cobrek and entered a product development collaboration focused on foam dosage form generic pharmaceutical products. The partnership has successfully yielded two commercialized foam-based products and two FDA approved foam-based products to be launched in Perrigo's fiscal year 2013. Cobrek earns revenues from a profit sharing agreement on partnered products and Perrigo is responsible for all commercial activities under the existing collaboration.
Perrigo chairman, president and chief executive officer, Joseph C. Papa said, "We continue to market the only generic foam products in the U.S. and expect to launch two additional products – generic versions of Luxiq (betamethasone valerate) Foam and Olux-E (clobetasol propionate) Foam 0.05% – during this fiscal year, which is a testament to the challenges of this dosage form and success of our partnership with Cobrek. Acquiring the remaining stake of Cobrek not already owned is the logical next step in this relationship and will allow us to continue to bring quality, affordable healthcare to our consumers and customers."

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity